Profusa Announces Progress Towards Satisfying the Conditions to Close of the Option Agreement with G3

Profusa advances G3 acquisition with $108M target revenue but profitability remains limited.

What the company is saying

Profusa, Inc. frames this update as a milestone in its acquisition of G3 Vision Labs, emphasizing progress on both operational and financial fronts. The company highlights receipt of G3’s audited and unaudited financials, satisfaction of key closing conditions, and ongoing compliance with Nasdaq listing standards. The narrative stresses near-term working capital sufficiency, achieved through a $0.7 million loan from Ascent Partners and the conversion of $10.7 million in debt and liabilities into non-voting convertible preferred stock. CEO Jack Stover expresses confidence in closing the G3 deal by year-end, using language such as 'timely progress' and 'on a good track.' The company also reiterates ongoing efforts to obtain CE mark approval for its Lumee Oxygen Platform, though no concrete regulatory milestones or dates are provided. The announcement foregrounds G3’s FY 2025 financials—$108 million revenue, $2.4 million net loss, $7.3 million EBITDA, and $5.0 million Adjusted EBITDA—while attributing one-time items to a $2 million COVID-19 claim recovery and Dominion acquisition costs.

What the data suggests

The disclosed numbers show G3 Vision Labs generated $108,021,457 in FY 2025 revenue but posted a net loss of $2,380,320, reflecting thin margins and limited profitability. EBITDA was $7,303,509, with Adjusted EBITDA at $4,957,839 and a 4.6% margin, after accounting for $2,345,670 in one-time items, including a $2 million COVID-19 claim recovery and transaction costs. Profusa has converted $10.7 million in debt and liabilities into preferred stock, each convertible into 1,000 common shares upon shareholder approval, signaling significant future dilution risk. The company borrowed $0.7 million in October to fund operations, indicating ongoing reliance on external capital. While Profusa claims sufficient near-term working capital and Nasdaq compliance, no standalone or pro forma combined financials for Profusa are disclosed, and there is no evidence of improved profitability or cash flow at the group level. The announcement provides no year-over-year comparisons, trend data, or concrete regulatory progress on the CE mark, limiting visibility into operational momentum.

Analysis

The announcement is generally positive in tone, highlighting progress on debt conversion, working capital, and regulatory milestones. Several claims are realised and supported by specific figures, such as the $10.7 million debt exchange, $0.7 million borrowing, and detailed FY 2025 financials for G3 Vision Labs, Inc. However, key forward-looking statements—such as progress toward CE mark approval and the anticipated closing of the G3 acquisition—are not yet realised and lack concrete timelines or binding commitments. The capital structure changes (debt-for-equity swaps, new borrowing) are significant, but the benefits (acquisition closing, regulatory approval) are not immediate and remain subject to further conditions. The financial data for G3 is detailed, but there is no trend or pro forma data for Profusa, and the combined entity's profitability remains uncertain. The language around being 'on track' and 'making progress' inflates the narrative relative to the actual, measurable progress disclosed.

Risk flags

• ●Execution risk on the G3 acquisition remains high, as closing is contingent on satisfaction of multiple conditions and shareholder approval, with no binding timeline or regulatory clearance disclosed. Failure to close would undermine the growth narrative and could leave Profusa with ongoing capital needs.
• ●Financial risk is elevated due to continued net losses at G3 ($2.4 million in FY 2025) and Profusa’s reliance on external funding, as evidenced by the recent $0.7 million borrowing and $10.7 million in debt-for-equity swaps. The conversion of preferred stock into 1,000 common shares each could result in substantial dilution for existing shareholders.
• ●Regulatory risk persists around the CE mark for the Lumee Oxygen Platform, as the company discloses only that it is 'making progress' without providing evidence of submissions, milestones, or expected approval dates. Delays or failure to obtain the CE mark would impact commercialization prospects.
• ●Disclosure risk is present, as the announcement lacks pro forma combined financials, trend data, or standalone Profusa results, making it difficult for investors to assess the true financial trajectory or synergies of the combined entity.

Bottom line

Profusa’s update delivers concrete financials for its G3 acquisition target—$108 million in revenue and $2.4 million net loss for FY 2025—but leaves key questions about profitability, integration, and dilution unresolved. The company has secured near-term liquidity through a $0.7 million loan and $10.7 million in debt conversion, but the preferred stock structure introduces significant dilution risk if converted. While management signals confidence in closing the G3 deal by year-end, this remains unconfirmed and subject to conditions. No new evidence is provided for progress on the CE mark or for operational improvements at Profusa itself. Investors should focus on the actual closing of the G3 transaction, the terms of shareholder approval for conversion, and any evidence of regulatory or commercial traction. The most important takeaway is that while headline revenue is substantial, sustained profitability and value creation remain unproven until after the acquisition closes and integration risks are addressed.

Announcement summary

(NASDAQ:PFSA) Profusa, Inc. announced that it has obtained sufficient working capital to fund its operations for the near term and is making progress in converting debt and liabilities to Preferred Stock. Profusa continues to advance towards obtaining CE mark approval for its Lumee Oxygen Platform. The company has made progress towards satisfying the conditions to close the Option Agreement with G3 Vision Labs, Inc., including receipt of G3’s consolidated PCAOB audited financial statements for FY 2025 and FY 2024, and unaudited consolidated financial statements for the six months ended June 30, 2026. Profusa received a Nasdaq compliance letter on September 9, 2026, confirming compliance with Listing Rules 5550(a)(2) and 5550(b)(1) (Bid Price and Equity Rules). To date, Profusa has entered exchange agreements totaling $10.7 million of debt and liabilities, which were exchanged for a newly designated series of non-voting convertible preferred stock, with each share of Preferred Stock convertible into 1,000 shares of Profusa common stock after stockholder approval. In October, Profusa borrowed $0.7 million under its current note agreement with Ascent Partners to fund near-term working capital needs. The company continues to manage costs effectively. Executive Chairman and CEO Jack Stover expressed satisfaction with the progress towards exercising the Option to acquire G3 and believes the company is on track to close by the end of the year. For FY 2025, the audited G3 combined company financial results show revenue of $108 million and a net loss of $2.4 million. The unaudited non-GAAP financial results for FY 2025 report EBITDA of $7.3 million and Adjusted EBITDA of $5.0 million, with an Adjusted EBITDA margin of 4.6%. Revenue for FY 2025 was $108,021,457, net loss was $2,380,320, interest expense was $3,414,450, depreciation and amortization was $2,933,024, and D&A included in cost of revenue was $3,336,355. Total one-time items for FY 2025 were $(2,345,670), including a $2 million settlement for the Acutis COVID-19 claim recovery, other one-time income items, and transaction costs related to the Dominion acquisition. Adjusted EBITDA for FY 2025 was $4,957,839. Profusa, Inc. holds registered trademarks in the United States, Canada, China, Japan, South Korea, and Australia.

Disagree with this article?